Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
CRMD's Cash to Debt is ranked higher than
79% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. CRMD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CRMD' s 10-Year Cash to Debt Range
Min: 0.11  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.78
CRMD's Equity to Asset is ranked higher than
62% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CRMD: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
CRMD' s 10-Year Equity to Asset Range
Min: -1.36  Med: 0.26 Max: 0.82
Current: 0.78
-1.36
0.82
F-Score: 5
Z-Score: 16.43
M-Score: 18.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -5512.02
CRMD's Operating margin (%) is ranked lower than
89% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. CRMD: -5512.02 )
Ranked among companies with meaningful Operating margin (%) only.
CRMD' s 10-Year Operating margin (%) Range
Min: -245750  Med: -125230.03 Max: -4710.05
Current: -5512.02
-245750
-4710.05
Net-margin (%) -4441.35
CRMD's Net-margin (%) is ranked lower than
88% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. CRMD: -4441.35 )
Ranked among companies with meaningful Net-margin (%) only.
CRMD' s 10-Year Net-margin (%) Range
Min: -456650  Med: -233735.85 Max: -10821.69
Current: -4441.35
-456650
-10821.69
ROE (%) -439.67
CRMD's ROE (%) is ranked lower than
96% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. CRMD: -439.67 )
Ranked among companies with meaningful ROE (%) only.
CRMD' s 10-Year ROE (%) Range
Min: -678.23  Med: -416.80 Max: -155.37
Current: -439.67
-678.23
-155.37
ROA (%) -116.31
CRMD's ROA (%) is ranked lower than
88% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. CRMD: -116.31 )
Ranked among companies with meaningful ROA (%) only.
CRMD' s 10-Year ROA (%) Range
Min: -507.14  Med: -196.95 Max: -116.99
Current: -116.31
-507.14
-116.99
ROC (Joel Greenblatt) (%) -20708.52
CRMD's ROC (Joel Greenblatt) (%) is ranked lower than
92% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. CRMD: -20708.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CRMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -73563.64  Med: -42147.06 Max: -35270.59
Current: -20708.52
-73563.64
-35270.59
EBITDA Growth (3Y)(%) 14.70
CRMD's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. CRMD: 14.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CRMD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -66.7  Med: -13.00 Max: 14.7
Current: 14.7
-66.7
14.7
EPS Growth (3Y)(%) 18.30
CRMD's EPS Growth (3Y)(%) is ranked higher than
75% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. CRMD: 18.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CRMD' s 10-Year EPS Growth (3Y)(%) Range
Min: -68.4  Med: -15.70 Max: 18.3
Current: 18.3
-68.4
18.3
» CRMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CRMD Guru Trades in Q2 2014

Paul Singer 781,440 sh (unchged)
» More
Q3 2014

CRMD Guru Trades in Q3 2014

Paul Singer 781,440 sh (unchged)
» More
Q4 2014

CRMD Guru Trades in Q4 2014

Paul Singer 781,440 sh (unchged)
» More
Q1 2015

CRMD Guru Trades in Q1 2015

Jim Simons 47,600 sh (New)
Paul Singer 1,500,200 sh (+91.98%)
Paul Singer 1,500,200 sh (+91.98%)
» More
» Details

Insider Trades

Latest Guru Trades with CRMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 13.19
CRMD's P/B is ranked lower than
84% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CRMD: 13.19 )
Ranked among companies with meaningful P/B only.
CRMD' s 10-Year P/B Range
Min: 0  Med: 0.00 Max: 61.5
Current: 13.19
0
61.5
P/S 379.78
CRMD's P/S is ranked lower than
180% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. CRMD: 379.78 )
Ranked among companies with meaningful P/S only.
CRMD' s 10-Year P/S Range
Min: 0  Med: 0.00 Max: 10793.6
Current: 379.78
0
10793.6
Current Ratio 4.57
CRMD's Current Ratio is ranked higher than
51% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. CRMD: 4.57 )
Ranked among companies with meaningful Current Ratio only.
CRMD' s 10-Year Current Ratio Range
Min: 0.1  Med: 2.49 Max: 10.33
Current: 4.57
0.1
10.33
Quick Ratio 4.35
CRMD's Quick Ratio is ranked higher than
51% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CRMD: 4.35 )
Ranked among companies with meaningful Quick Ratio only.
CRMD' s 10-Year Quick Ratio Range
Min: 0.1  Med: 2.49 Max: 10.33
Current: 4.35
0.1
10.33
Days Inventory 371.31
CRMD's Days Inventory is ranked lower than
89% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. CRMD: 371.31 )
Ranked among companies with meaningful Days Inventory only.
CRMD' s 10-Year Days Inventory Range
Min: 72.28  Med: 147.24 Max: 222.19
Current: 371.31
72.28
222.19
Days Sales Outstanding 121.08
CRMD's Days Sales Outstanding is ranked lower than
80% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. CRMD: 121.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRMD' s 10-Year Days Sales Outstanding Range
Min: 154.5  Med: 259.75 Max: 365
Current: 121.08
154.5
365

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.58
CRMD's Price/Net Cash is ranked lower than
69% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. CRMD: 14.58 )
Ranked among companies with meaningful Price/Net Cash only.
CRMD' s 10-Year Price/Net Cash Range
Min: 2.11  Med: 5.58 Max: 41
Current: 14.58
2.11
41
Price/Net Current Asset Value 12.96
CRMD's Price/Net Current Asset Value is ranked lower than
67% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. CRMD: 12.96 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CRMD' s 10-Year Price/Net Current Asset Value Range
Min: 2.05  Med: 5.18 Max: 36.44
Current: 12.96
2.05
36.44
Price/Tangible Book 12.96
CRMD's Price/Tangible Book is ranked lower than
78% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. CRMD: 12.96 )
Ranked among companies with meaningful Price/Tangible Book only.
CRMD' s 10-Year Price/Tangible Book Range
Min: 2.05  Med: 5.18 Max: 36.44
Current: 12.96
2.05
36.44
Earnings Yield (Greenblatt) (%) -9.02
CRMD's Earnings Yield (Greenblatt) (%) is ranked lower than
62% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. CRMD: -9.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CRMD' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -34.6  Med: 0.00 Max: 0
Current: -9.02
-34.6
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Cormedix Inc was organized as a Delaware corporation on July 28, 2006 under the name Picton Holding Company, Inc. and changed it to CorMedix Inc. on January 18, 2007. The Company develops and seeks to commercialize products for the treatment of cardiac, renal and infectious diseases. Its principal product under development includes CRMD003, an antimicrobial/anticoagulant solution applied in the prevention of catheter related bloodstream infections and maintenance of catheter patency in central venous catheters used for vascular access in hemodialysis patients. Its products also include CRMD004, a pressure sensitive gel that is in pre-clinical Phase.
» More Articles for CRMD

Headlines

Articles On GuruFocus.com
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CorMedix, Inc. of Pendency of Clas Jul 16 2015 
Paul Singer's Latest Portfolio Increases and Reduction Mar 04 2015 
CorMedix Receives Approval From FDA to Initiate a Clinical Trial for Neutrolin in the US Oct 27 2014 
Weekly CFO Buys Highlight: CEP, JNS, CRMD, VAC, TICC Dec 26 2011 
Weekly CFO Buys Highlight: POL, ARAY, ZBB, CRMD, VRX Dec 19 2011 
CORMEDIX INC Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
SECURITIES ALERT: The Rosen Law Firm Announces the Filing of a Securities Class Action Lawsuit... Jul 31 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CorMedix, Inc. of Pendency of... Jul 31 2015
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against CorMedix, Inc. Jul 24 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in... Jul 24 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of CorMedix, Inc. of Pendency of Class... Jul 22 2015
CORMEDIX INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial... Jul 17 2015
CorMedix Inc. Announces Decision to Initiate Neutrolin Phase 3 Clinical Study Jul 17 2015
TRADING ALERT: The Rosen Law Firm Reminds CorMedix, Inc. Investors of the Important Deadline in the... Jul 17 2015
CRMD INVESTOR ALERT: Investigation of CorMedix, Inc. Announced by The Law Offices of Howard G. Smith Jul 17 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CorMedix, Inc. of Pendency of... Jul 16 2015
Robbins Arroyo LLP: CorMedix, Inc. (CRMD) Misled Shareholders According to a Recently Filed Class... Jul 13 2015
Morgan & Morgan Announces That a Class Action Lawsuit Has Been Filed Against CorMedix, Inc. -- CRMD Jul 10 2015
Stull, Stull & Brody Announces Class Action Suit on Behalf of Purchasers of Common Shares of... Jul 09 2015
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against CorMedix, Inc. Jul 09 2015
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been... Jul 08 2015
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of... Jul 08 2015
EQUITY ALERT: The Rosen Law Firm Announces the Filing of a Securities Class Action Lawsuit Against... Jul 07 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CorMedix, Inc. of Pendency of... Jul 07 2015
Pomerantz Law Firm Announces the Filing of a Class Action Against CorMedix, Inc. and Certain... Jul 06 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CorMedix, Inc. -... Jun 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK